Open Access

Awareness of Chemotherapy and Its Side Effects and Their Influence on Quality of Life Among Breast Cancer Patients in a Nigerian Teaching Hospital

4 BNSc, Department of Nursing Science, Faculty of Health Sciences, National Open University of Nigeria, Owerri Study Centre, Nigeria; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 PhD, Department of Nursing Science, Faculty of Health Sciences, National Open University of Nigeria, Owerri Study Centre, Nigeria
4 PhD, Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 PhD, Faculty of Health, Wellbeing & Social Care, Oxford Brookes University, GBS Partnership, Birmingham Campus, United Kingdom; and PENKUP Research Institute, Birmingham, United Kingdom.
4 MPH, Family Health International, Ukraine; and PENKUP Research Institute, Birmingham, United Kingdom; Department of Multidisciplinary Studies & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 FMCPath, Histopathology Department, Faculty of Basic Clinical Sciences, College of Medicine, Chukwuemeka Odumegwu Ojukwu University, Awka, Anambra State, Nigeria; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 MPH, Department of Medical Laboratory Science, Faculty of Applied Health Science, Edo State University, Iyamho, Edo State, Nigeria; Department of Medical Microbiology, Faculty of Medical Laboratory Science, Ambrose Alli University, Ekpoma, Edo State, Nigeria; and Department of Interdisciplinary Research and Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 FWACS, Department of Ophthalmology, Federal Teaching Hospital, Lokoja, Nigeria; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 PhD, School of Health and Sports Science, Regent College, London, United Kingdom; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 MHPM, Department of Oral Diagnosis and Dental Public Health, D’ Dentist Place Dental Clinic, Owerri, Nigeria; Department of Oral Pathology, D’ Dentist Place Dental Clinic, Owerri, Nigeria; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 MSc, World Health Organisation, Abuja, Nigeria; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 FMCPath, Department of Anatomic Pathology and Forensic Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 MSc, Department of Health, Wellbeing & Social Care, Global Banking School, Oxford Brookes University Partnership, Birmingham Campus, Birmingham, United Kingdom; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 B. Pharm, School of Pharmaceutical Sciences, Nnamdi Azikiwe University, Anambra, Nigeria; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 MBBS, Department of Interdisciplinary Research and Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 FMCS, Department of Plastic Surgery, National Orthopaedic Hospital, Enugu, Nigeria; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 MBChB, Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 MBBS, Outpatient Department, EFCC Clinic, Abuja, Nigeria; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 MSc, Department of Obstetrics and Gynaecology, Nnamdi Azikiwe University, Awka, Nigeria; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 MRSC (Ed), Surgery Department, Nisa Garki Hospital, Abuja; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom
4 World Health Organization, United Nations House, Abuja, Nigeria; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 MSc, Liverpool Women’s Hospital NHS Foundation Trust, United Kingdom; and Department of Interdisciplinary Research & Statistics, PENKUP Research Institute, Birmingham, United Kingdom.
4 Tees, Esk and Wear Valleys NHS Foundation Trust, Durham, United Kingdom; and Department of Interdisciplinary Research and Statistics, PENKUP Research Institute, Birmingham, United Kingdom

Abstract

Breast cancer remains a leading cause of morbidity among women globally, with chemotherapy forming a central component of treatment across disease stages. While effective in controlling disease progression, chemotherapy is associated with a range of side effects that can adversely affect patients’ quality of life. This study examines the relationship between awareness of chemotherapy side effects and quality of life among breast cancer patients within a clinical setting.

A descriptive cross-sectional design was employed, drawing on data from 80 patients receiving chemotherapy. Data were collected using a structured questionnaire assessing awareness of chemotherapy, awareness of side effects, and perceived impact on quality of life. Descriptive statistics were used to summarise responses and examine patterns across key variables.

Findings indicate that patients generally demonstrate a high level of awareness of chemotherapy (grand mean = 4.05) and its associated side effects (grand mean = 3.64). Awareness was strongest for visible and frequently experienced symptoms such as hair loss, nausea, and fatigue. However, gaps were observed in more complex aspects of treatment, particularly in relation to treatment sequencing and administration cycles. Quality of life outcomes revealed a consistent pattern of disruption, with respondents reporting fatigue, reduced physical functioning, increased dependence on others, decreased social participation, and heightened anxiety. The overall impact on quality of life was substantial (grand mean = 3.51).

Importantly, higher levels of awareness were associated with better coping and relatively improved quality of life, suggesting that awareness plays a meaningful role in shaping patient experience during treatment. These findings highlight the need for sustained patient-centred education that extends beyond basic information provision.

The study concludes that while awareness of chemotherapy and its side effects is generally high, it remains uneven and insufficient in critical areas. Strengthening patient education and ongoing communication within oncology care may improve coping, enhance quality of life, and support more effective engagement with treatment.

Keywords

References

📄 Almohammadi, A., Alquarni, A., Alraddadi, R., & Alzahrani, F. (2020). Assessment of patients’ knowledge in managing side effects of chemotherapy. Psycho-Oncology, 29(6), 1033–1040.
📄 Bailey, L. R., Craft, M., Bert, S. S., & Carlson, B. W. (2024, March). The Impact of Chemotherapy-Related Cognitive Impairment on Social Roles and Well-Being in Breast Cancer Survivors. In Oncology Nursing Forum (Vol. 51, No. 2).
📄 Bilodeau, K., Henriksen, C., Lee, V., Vachon, M. F., Charpentier, D., Folch, N., ... & Fernandez, N. (2022). The experiential learning pathway of cancer survivors as they recover their lives post-treatment: A qualitative study. Global Qualitative Nursing Research, 9, 23333936221083026.
📄 Boman, L. E., Sandelin, K., Wengström, Y., & Silén, C. (2017). Patients’ learning and understanding during their breast cancer trajectory. Patient education and counselling, 100(5), 795-804.
📄 Bottomley, A., Reijneveld, J. C., Koller, M., Flechtner, H., Tomaszewski, K. A., Greimel, E., ... & Van De Poll-franse, L. (2019). Current state of quality of life and patient-reported outcomes research. European Journal of Cancer, 121, 55-63.
📄 Cooper, L., Deal, A. M., Aman, C., Page, A., Muss, H., Nyrop, K. A., & Knowlton, S. E. (2024). Identifying pre-habilitation targets for the mitigation of long-term side effects of chemotherapy in patients with early breast cancer. Supportive Care in Cancer, 32(8), 530.
📄 de Ligt, K. M., de Rooij, B. H., Koppert, L. B., van de Poll-Franse, L. V., Velikova, G., & Cardoso, F. (2023, December). Patient-reported outcome measures to improve the care continuum for patients with metastatic breast cancer: opportunities and Implications for nursing practice. In Seminars in Oncology Nursing (Vol. 39, No. 6, p. 151510). WB Saunders.
📄 Faller, H., Schuler, M., Richard, M., Heckl, U., Weis, J., & Küffner, R. (2013). Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: Systematic review and meta-analysis. Journal of Clinical Oncology, 31(6), 782–793. https://doi.org/10.1200/JCO.2011.40.8922
📄 Henderson, F. M., Cross, A. J., & Baraniak, A. R. (2019). ‘A new normal with chemobrain’: experiences of the impact of chemotherapy-related cognitive deficits in long-term breast cancer survivors. Health psychology open, 6(1), 2055102919832234.
📄 Hurvitz, S. A., Bardia, A., Quiroga, V., Park, Y. H., Blancas, I., Alonso-Romero, J. L., ... & Fasching, P. A. (2023). Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. The Lancet Oncology, 24(9), 1029-1041.
📄 Husson, O., Mols, F., & van de Poll-Franse, L. V. (2011). The relation between information provision and health-related quality of life among cancer survivors: A systematic review. Annals of Oncology, 22(4), 761–772. https://doi.org/10.1093/annonc/mdq413
📄 Janelsins, M. C., Heckler, C. E., Peppone, L. J., et al. (2016). Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: An analysis from a nationwide, multicenter, prospective longitudinal study. Journal of Clinical Oncology, 35(5), 506–514. https://doi.org/10.1200/JCO.2016.68.5826
📄 Kim, H., Sefcik, J.S. and Bradway, C. (2017), Characteristics of Qualitative Descriptive Studies: A Systematic Review. Res Nurs Health, 40: 23-42. https://doi.org/10.1002/nur.21768
📄 Kotronoulas, G., Kearney, N., Maguire, R., Harrow, A., Di Domenico, D., Croy, S., & MacGillivray, S. (2014). The value of patient-reported outcome measures in cancer care. Journal of Clinical Oncology, 32(14), 1480–1501. https://doi.org/10.1200/JCO.2013.53.5948
📄 Lanfear, C., & Harding, S. (2023). The effectiveness of nurse‐led care in supporting self‐management in patients with cancer: A systematic review. Journal of clinical nursing, 32(23-24), 7996-8006.
📄 Lôbo, S. A., Fernandes, A. F. C., Almeida, P. C. D., Carvalho, C. M. D. L., & Sawada, N. O. (2014). Quality of life in women with breast cancer undergoing chemotherapy. Acta Paulista de Enfermagem, 27, 554-559.
📄 McCaughan, E., Parahoo, K., Hueter, I., Northouse, L., & Martin, F. (2017). Online support groups for women with breast cancer. Cochrane Database of Systematic Reviews, 3, CD011652. https://doi.org/10.1002/14651858.CD011652.pub2
📄 Ng, C. G., Mohamed, S., Kaur, K., Sulaiman, A. H., Zainal, N. Z., Taib, N. A., & MyBCC Study group. (2017). Perceived distress and its association with depression and anxiety in breast cancer patients. PloS one, 12(3), e0172975.
📄 Obispo, B., Bailleux, C., Cantos, B., Zamora, P., Jhawar, S. R., Varghese, J., ... & Xu, X. (2025). Long-term adverse events following early breast cancer treatment with a focus on the BRCA-mutated population. Cancers, 17(15), 2506.
📄 Ogunniyi, T. J., Fatokun, B. S., Isah, K. O., Abdulbaki, A., Emiola, A. R., & Batisani, K. (2025). Current status of cancer diagnosis and treatment in Nigeria. Health Science Reports, 8(6), e70877.
📄 Olayide, A., Isiaka, A., Ganiyu, R., Samuel, O., Halimat, A., Olalekan, O., ... & Anya, R. (2023). Breast cancer treatment and outcomes in Nigeria: a systematic review and meta-analysis. Asian Pacific Journal of Cancer Care, 8(3), 591-598.
📄 Rodriguez-Gonzalez, A., Velasco-Durantez, V., Martin-Abreu, C., Cruz-Castellanos, P., Hernandez, R., Gil-Raga, M., ... & Calderon, C. (2022). Fatigue, emotional distress, and illness uncertainty in patients with metastatic cancer: results from the prospective NEOETIC_SEOM study. Current Oncology, 29(12), 9722-9732.
📄 Savitri, M., Sutanto, H., Romadhon, P. Z., Diansyah, M. N., Amrita, P. N. A., Hendarsih, E., ... & Ashariati, A. (2025). Quality of Life Following Breast Cancer Chemotherapy: A Narrative Review of Patient-Reported Outcomes and Supportive Care. SN Comprehensive Clinical Medicine, 7(1), 432.
📄 Setia, M. S. (2016). Methodology series module 3: Cross-sectional studies. Indian Journal of Dermatology, 61(3), 261–264. https://doi.org/10.4103/0019-5154.182410
📄 Taber, K. S. (2018). The use of Cronbach’s alpha when developing and reporting research instruments in science education. Research in Science Education, 48(6), 1273–1296. https://doi.org/10.1007/s11165-016-9602-2
📄 Trisyani, Y., Nuraeni, A., Anna, A., Priambodo, A. P., & Sugiharto, F. (2026). Nursing Interventions for Symptom Management in Breast Cancer: A Systematic Review. International Journal of Women's Health, 1-14.
📄 Villacampa, G., Navarro, V., Matikas, A., Ribeiro, J. M., Schettini, F., Tolosa, P., ... & Pascual, T. (2024). Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis. JAMA oncology, 10(10), 1331-1341.
📄 World Health Organization. (2024). Breast cancer fact sheet. https://www.who.int/news-room/fact-sheets/detail/breast-cancer, Available at: 18 November, 2025)
📄 Zdenkowski, N., Kuper-Hommel, M. J., Niman, S. M., Francis, P. A., Baron-Hay, S., Fox, W., ... & Loi, S. (2025). Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial. The Lancet Oncology, 26(3), 367-377.

Most read articles by the same author(s)

Similar Articles

1-10 of 23

You may also start an advanced similarity search for this article.